BIOMAT Database Logo BIOMAT Database Logo

Prescription compliance or illicit designer drug abuse? 2012

Matthew S Petrie, and Kara L Lynch, and Alan H B Wu, and Angela A Steinhardt, and Gary L Horowitz
Department of Laboratory Medicine, San Francisco General Hospital, University of California, San Francisco, San Francisco, CA 94110, USA. Matthew.S.Petrie@kp.org

UI MeSH Term Description Entries
D007118 Immunoassay A technique using antibodies for identifying or quantifying a substance. Usually the substance being studied serves as antigen both in antibody production and in measurement of antibody by the test substance. Immunochromatographic Assay,Assay, Immunochromatographic,Assays, Immunochromatographic,Immunoassays,Immunochromatographic Assays
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010879 Piperazines Compounds that are derived from PIPERAZINE.
D003429 Cross Reactions Serological reactions in which an antiserum against one antigen reacts with a non-identical but closely related antigen. Cross Reaction,Reaction, Cross,Reactions, Cross
D005189 False Positive Reactions Positive test results in subjects who do not possess the attribute for which the test is conducted. The labeling of healthy persons as diseased when screening in the detection of disease. (Last, A Dictionary of Epidemiology, 2d ed) False Positive Reaction,Positive Reaction, False,Positive Reactions, False,Reaction, False Positive,Reactions, False Positive
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000928 Antidepressive Agents Mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. Several MONOAMINE OXIDASE INHIBITORS are useful as antidepressants apparently as a long-term consequence of their modulation of catecholamine levels. The tricyclic compounds useful as antidepressive agents (ANTIDEPRESSIVE AGENTS, TRICYCLIC) also appear to act through brain catecholamine systems. A third group (ANTIDEPRESSIVE AGENTS, SECOND-GENERATION) is a diverse group of drugs including some that act specifically on serotonergic systems. Antidepressant,Antidepressant Drug,Antidepressant Medication,Antidepressants,Antidepressive Agent,Thymoanaleptic,Thymoanaleptics,Thymoleptic,Thymoleptics,Antidepressant Drugs,Agent, Antidepressive,Drug, Antidepressant,Medication, Antidepressant
D014196 Trazodone A serotonin uptake inhibitor that is used as an antidepressive agent. It has been shown to be effective in patients with major depressive disorders and other subsets of depressive disorders. It is generally more useful in depressive disorders associated with insomnia and anxiety. This drug does not aggravate psychotic symptoms in patients with schizophrenia or schizoaffective disorders. (From AMA Drug Evaluations Annual, 1994, p309) AF-1161,Apo-Trazodone,Deprax,Desyrel,Gen-Trazodone,Molipaxin,Novo-Trazodone,Nu-Trazodone,PMS-Trazodone,Ratio-Trazodone,Thombran,Tradozone,Trazodon Hexal,Trazodon-Neuraxpharm,Trazodone Hydrochloride,Trazon,Trittico,AF 1161,AF1161,Apo Trazodone,Gen Trazodone,Novo Trazodone,Nu Trazodone,PMS Trazodone,Ratio Trazodone,RatioTrazodone,Trazodon Neuraxpharm,TrazodonNeuraxpharm
D015198 Designer Drugs Drugs designed and synthesized, often for illegal street use, by modification of existing drug structures (e.g., amphetamines). Of special interest are MPTP (a reverse ester of meperidine), MDA (3,4-methylenedioxyamphetamine), and MDMA (3,4-methylenedioxymethamphetamine). Many drugs act on the aminergic system, the physiologically active biogenic amines. Customized Drug,Customized Drugs,Designer Drug,Drug, Customized,Drug, Designer,Drugs, Customized,Drugs, Designer

Related Publications

Matthew S Petrie, and Kara L Lynch, and Alan H B Wu, and Angela A Steinhardt, and Gary L Horowitz
Do prescription drug monitoring programs encourage prescription - or illicit - opioid abuse?
January 2021, Substance abuse,
Matthew S Petrie, and Kara L Lynch, and Alan H B Wu, and Angela A Steinhardt, and Gary L Horowitz
Prescription drug abuse in Canada and the diversion of prescription drugs into the illicit drug market.
January 2005, Canadian journal of public health = Revue canadienne de sante publique,
Matthew S Petrie, and Kara L Lynch, and Alan H B Wu, and Angela A Steinhardt, and Gary L Horowitz
Drug abuse: designer drugs.
January 1991, Advancing clinical care : official journal of NOAADN,
Matthew S Petrie, and Kara L Lynch, and Alan H B Wu, and Angela A Steinhardt, and Gary L Horowitz
Drug abuse and illicit drug trafficking.
June 1998, The Medical journal of Australia,
Matthew S Petrie, and Kara L Lynch, and Alan H B Wu, and Angela A Steinhardt, and Gary L Horowitz
Prevalence of illicit drug abuse.
July 2003, Pain physician,
Matthew S Petrie, and Kara L Lynch, and Alan H B Wu, and Angela A Steinhardt, and Gary L Horowitz
Prescription drug abuse.
March 2014, The Journal of the Michigan Dental Association,
Matthew S Petrie, and Kara L Lynch, and Alan H B Wu, and Angela A Steinhardt, and Gary L Horowitz
Prescription drug abuse.
February 1985, Canadian Medical Association journal,
Matthew S Petrie, and Kara L Lynch, and Alan H B Wu, and Angela A Steinhardt, and Gary L Horowitz
Prescription drug abuse.
August 2014, Annals of internal medicine,
Matthew S Petrie, and Kara L Lynch, and Alan H B Wu, and Angela A Steinhardt, and Gary L Horowitz
Prescription drug abuse.
August 2014, Annals of internal medicine,
Matthew S Petrie, and Kara L Lynch, and Alan H B Wu, and Angela A Steinhardt, and Gary L Horowitz
Prescription drug abuse.
August 2014, Annals of internal medicine,
Copied contents to your clipboard!